Search This Blog

Saturday, January 15, 2022

Think you had COVID despite testing negative? What to know about antibody tests

 The omicron variant of COVID-19 has caused a surge in symptoms and positive cases across the United States, and since a few of the symptoms resemble a common cold, one question some are asking is: Did I have COVID?

That question is exemplified even more when you take into account the reliability of at-home tests, as well as the difficulty in finding at-home tests.

If you experienced symptoms and tested negative but still think you had COVID-19, you can take an antibody or serology test, which according to the Centers for Disease Control and Prevention (CDC), can search for antibodies that fight the coronavirus in your blood.

Health experts have warned against using an antibody test to diagnose COVID or determine immunity, though.

“An antibody test may not show if you have a current infection because it can take 1 to 3 weeks after the infection for your body to make antibodies,” the CDC says.

Additionally, anyone who has been vaccinated already will have antibodies. The immune system creates antibodies, or proteins, to help ward off infections after you have either been infected with COVID-19 or after you have been vaccinated against the virus.

“(An antibody test) alone cannot be used for a diagnosis of a previous COVID infection,” said Dr. Sandra Adams, a professor of biology and virologist at Montclair State University, “because a positive antibody test will also detect the antibodies produced as a result of vaccination.”

How to get an antibody test

You can get an antibody test through your doctor, health care provider, and stand-alone laboratories such as Labcorp or Quest.

It is recommended to check with your physician or other healthcare professional to see if you are eligible for an antibody test.

The U.S. Food and Drug Administration recently warned that certain antibody tests have a high risk of false results.

When not to get an antibody test

The CDC says there are several instances in which taking an antibody test is not advisable:

  • If you are currently infected with COVID-19
  • To determine immunity against COVID-19 after vaccination
  • To decide if someone needs to receive a vaccine

Omicron variant spreads across China

 With the opening of the Beijing Winter Olympics getting near, Chinese authorities are becoming increasingly nervous about the spread of the Omicron variant of the coronavirus.

Last Sunday, two people in Tianjin, a city neighboring Beijing, were found infected with the Omicron variant. Municipal authorities have since conducted two rounds of PCR tests targeting the city's entire population.

The tests turned up 181 new coronavirus cases by Friday although it is unknown whether the number includes any Omicron cases.

The authorities launched the third round of citywide testing on Saturday.

City officials say around 345,000 university students, faculty members and staff have left the city for winter recess since December 23. Of them, a student was found infected with Omicron in Anyang, Henan Province, while two more were confirmed with the variant in Dalian, Liaoning Province.

Elsewhere in the country, eight new Omicron cases were confirmed on Friday in an area neighboring Macao in the southern province of Guangdong.

With around three weeks to go before the opening of the Olympics, the Chinese government is scrambling to rein in infections by banning entry into Beijing from the regions where new cases have been confirmed within a two-week period.


https://www3.nhk.or.jp/nhkworld/en/news/20220115_13/

1 in 9 recent virus cases in Israel are reinfections — report

 Around one in nine of the recent cases of coronavirus diagnosed in Israel were people who have previously recovered from an infection, according to a Friday report.

The Kan public broadcaster said 11 percent of cases confirmed over the past few days were reinfections.

There were no details given as to the percentage of those individuals who had been vaccinated in addition to having recovered from the virus, but the report said that a large proportion of them were at least partially inoculated.

Israel is currently seeing an unprecedented wave of infections driven by the Omicron variant.

Health officials believe the country could see around 100,000 new daily cases reported in the coming days, with the true number of infections in fact significantly higher due to changes in testing protocols.

Health Ministry data on Friday showed 40,430 new cases diagnosed in the previous 24 hours, a figure also believed by officials to be a significant undercount.

People shop at the Mahane Yehuda market in Jerusalem on January 13, 2022 (Olivier Fitoussi/Flash90)

The number of patients seriously ill with COVID-19 is climbing, reaching 306, up from 283 a day earlier. Of those patients, 86 were critically ill and 76 were on ventilators.

Israel is, however, reportedly seeing a slow rise in the number of seriously ill patients who need to be ventilated due to infection with the Omicron variant, compared to previous waves.

Though highly infectious, the Omicron strain now dominating the country is considered less virulent than previous variants, and Health Ministry figures show that the number of both seriously ill patients and deaths is lower than rates seen in the past.

Of the 319,572 virus tests carried out Thursday, 12.65% confirmed infection, the latest data showed, in a continuation of the high positive rate seen over the past week. There were close to 250,000 confirmed active COVID-19 patients overall across the country.

A health worker carries out a COVID-19 rapid antigen test in Jerusalem, on January 12, 2022 (Olivier Fitoussi/Flash90)

Nonetheless, infections drove 38,605 more people into isolation through exposure to a known virus carrier, bringing the total in quarantine due to exposure to 178,988 in addition to the 248,192 active patients.

On Thursday, new rules for quarantine began, shortening isolation for asymptomatic COVID patients from 10 days down to seven. But those still displaying symptoms throughout the full week will be required to keep isolating for a total of 10 days.

https://www.timesofisrael.com/one-in-nine-recent-virus-cases-in-israel-are-reinfections-report/

Some COVID patients still infectious after more than 2 months, study warns

 People who contract COVID-19 could still be infectious for more than two months, warns new research. Of course, remaining contagious for this long is far less likely, but scientists hope to expand the study to get a better idea of just how many people could be long carriers.

Researchers at the University of Exeter in England report that 13 percent of patients are still infectious and show clinically-relevant levels of the virus after 10 days of quarantine. In the most extreme of these cases, individuals were still carrying the virus for 68 days. There is nothing “clinically remarkable” about the people who remain with high levels of the virus, according to the study, which means it could happen to anyone.

For the study, researchers applied a new test on 176 people who had tested positive on standard PCRs to determine whether the virus was still active. The results suggest the new test should be applied in settings where people are vulnerable to stop the spread of COVID-19.

“While this is a relatively small study, our results suggest that potentially active virus may sometimes persist beyond a 10 day period, and could pose a potential risk of onward transmission,” says study co-author Lorna Harries, a professor at the University of Exeter Medical School, in a statement. “Furthermore, there was nothing clinically remarkable about these people, which means we wouldn’t be able to predict who they are”

Harries and her team warn that people should still be cautious about those who were recently infected. That’s especially the case after the Centers for Disease Control and Prevention lowered recommended isolation time to five days for infected patients.

“In some settings, such as people returning to care homes after illness, people continuing to be infectious after ten days could pose a serious public health risk,” says lead author Dr. Merlin Davies. “We may need to ensure people in those setting have a negative active virus test to ensure people are no longer infectious. We now want to conduct larger trials to investigate this further.”

It wasn’t mentioned in the media release as to whether the team is in the process of following up with a larger study.

The research is published in the Journal of Infectious Diseases.

https://pix11.com/news/coronavirus/some-covid-patients-still-infectious-after-more-than-2-months-study-warns/

No Omicron immunity without booster, study finds

 An additional “booster” dose of Moderna or Pfizer mRNA-based vaccine is needed to provide immunity against the Omicron variant of SARS-CoV-2, the virus that causes COVID-19, according to a study by researchers at the Ragon Institute of MGH, MIT and Harvard. The results of this study, reported in the journal Cell, indicate that traditional dosing regimens of COVID-19 vaccines available in the United States do not produce antibodies capable of recognizing and neutralizing the Omicron variant.

In late November, health officials in South Africa reported that a previously unknown variant of SARS-CoV-2 was rapidly spreading throughout the country. The variant, given the name Omicron by the World Health Organization, would soon prove to be far more transmissible than Delta, the variant that previously had caused the majority of COVID-19 infections. “People desperately wanted to know whether current vaccines protect against Omicron,” says the senior author of the Cell paper, Alejandro Balazs, whose laboratory at the Ragon Institute investigates how to engineer immunity against infectious diseases.

To find answers, Balazs collaborated with a team that included the lead author of the Cell paper, Wilfredo F. Garcia-Beltran, a clinical pathology resident at MGH and a clinician-scientist fellow at the Ragon Institute. The first step was to construct a harmless version of Omicron known as a “pseudovirus” that could be used in the laboratory to evaluate the effectiveness of the three COVID-19 vaccines available in the United States, which include the two-dose Pfizer and Moderna injections and the one-dose Johnson & Johnson vaccine. The pseudovirus that Balazs and colleagues created mimicked the behavior of Omicron, which has 34 mutations on its “spike” protein that are not found on the original strain of SARS-Cov-2 first detected in Wuhan, China, in December 2019. Scientists believe that these mutations may be partially responsible for Omicron’s rapid spread throughout the world.

Next, Garcia-Beltran worked with colleagues at MGH, including hematology-oncology fellow Vivek Naranbhai, to acquire blood samples from 239 individuals who had been fully vaccinated with one of the three COVID-19 vaccines. The study subjects included employees within the Massachusetts General Brigham health care system and residents of Chelsea, Massachusetts, a community with a high rate of COVID-19 infections. “It was important to us to have a diverse population represented in the study,” says Garcia-Beltran. Included in this group were 70 men and women who had received a third booster dose of either the Pfizer or Moderna vaccine, according to recommendations by the Centers for Disease Control and Prevention.

The blood samples were used to measure how effectively each vaccine induces production of protective immunity in the form of antibodies against the Omicron pseudovirus, as well as the Delta and wild type viruses. The results were striking. “We detected very little neutralization of the Omicron variant pseudovirus when we used samples taken from people who were recently vaccinated with two doses of mRNA vaccine or one dose of Johnson & Johnson,” says Balazs. “But individuals who received three doses of mRNA vaccine had very significant neutralization against the Omicron variant.”

It’s not yet clear why an mRNA booster dramatically improves immune protection against Omicron, but Garcia-Beltran says one possibility is that an additional dose creates antibodies that bind more tightly to the spike protein, increasing their effectiveness. Also, a booster dose may generate antibodies that target regions of the spike protein that are common to all forms of SARS-CoV-2. Both theories may be true, says Garcia-Beltran.

Balazs notes that the three-dose mRNA vaccine regimen — that is, the traditional two doses and a booster of Pfizer or Moderna vaccines — provides somewhat lower levels of neutralizing antibodies against Omicron than it does against the COVID-19 wild type strain or Delta variant. But the study’s results strongly support the CDC’s advice that COVID-19 booster shots are appropriate for anyone 16 and older, and that mRNA vaccines are preferred.

Balazs is a principal investigator at the Ragon Institute and an assistant professor of Medicine at Harvard Medical School. Garcia-Beltran recently established his own laboratory at the Ragon Institute.

This work was supported by the Peter and Ann Lambertus Family Foundation, the Massachusetts Consortium on Pathogenesis Readiness, the National Institutes of Health, and the German Center for Infection Research.

https://news.harvard.edu/gazette/story/2022/01/no-omicron-immunity-without-booster-study-finds/

Expect more worrisome variants after Omicron, scientists say

 Get ready to learn more Greek letters. Scientists warn that Omicron's whirlwind advance practically ensures it won't be the last version of the coronavirus to worry the world.

Every infection provides a chance for the virus to mutate, and Omicron has an edge over its predecessors: It spreads way faster despite emerging on a planet with a stronger patchwork of immunity from vaccines and prior illness.

That means more people in whom the virus can further evolve. Experts don't know what the next variants will look like or how they might shape the pandemic, but they say there's no guarantee the sequels of omicron will cause milder illness or that existing vaccines will work against them.

They urge wider vaccination now, while today's shots still work.

"The faster Omicron spreads, the more opportunities there are for mutation, potentially leading to more variants," Leonardo Martinez, an infectious disease epidemiologist at Boston University, said.

Since it emerged in mid-November, Omicron has raced across the globe like fire through dry grass. Research shows the variant is at least twice as contagious as Delta and at least four times as contagious as the original version of the virus.

Omicron is more likely than Delta to reinfect individuals who previously had COVID-19 and to cause "breakthrough infections" in vaccinated people while also attacking the unvaccinated. The World Health Organization reported a record 15 million new COVID-19 cases for the week of Jan. 3-9, a 55% increase from the previous week.

Along with keeping comparatively healthy people out of work and school, the ease with which the variant spreads increases the odds the virus will infect and linger inside people with weakened immune systems - giving it more time to develop potent mutations.

"It's the longer, persistent infections that seem to be the most likely breeding grounds for new variants," said Dr. Stuart Campbell Ray, an infectious disease expert at Johns Hopkins University. "It's only when you have very widespread infection that you're going to provide the opportunity for that to occur."

Because Omicron appears to cause less severe disease than delta, its behaviour has kindled hope that it could be the start of a trend that eventually makes the virus milder like a common cold.

It's a possibility, experts say, given that viruses don't spread well if they kill their hosts very quickly. But viruses don't always get less deadly over time.

A variant could also achieve its main goal - replicating - if infected people developed mild symptoms initially, spread the virus by interacting with others, then got very sick later, Ray explained by way of example.

"People have wondered whether the virus will evolve to mildness. But there's no particular reason for it to do so," he said. "I don't think we can be confident that the virus will become less lethal over time."

Getting progressively better at evading immunity helps a virus to survive over the long term. When SARS-CoV-2 first struck, no one was immune. But infections and vaccines have conferred at least some immunity to much of the world, so the virus must adapt.

There are many possible avenues for evolution. Animals could potentially incubate and unleash new variants. Pet dogs and cats, deer and farm-raised mink are only a few of the animals vulnerable to the virus, which can potentially mutate within them and leap back to people.

Another potential route: With both Omicron and delta circulating, people may get double infections that could spawn what Ray calls "Frankenvariants," hybrids with characteristics of both types.

When new variants do develop, scientists said it's still very difficult to know from genetic features which ones might take off. For example, Omicron has many more mutations than previous variants, around 30 in the spike protein that lets it attach to human cells. But the so-called IHU variant identified in France and being monitored by the WHO has 46 mutations and doesn't seem to have spread much at all.

To curb the emergence of variants, scientists stress continuing with public health measures such as masking and getting vaccinated. While Omicron is better able to evade immunity than delta, experts said, vaccines still offer protection and booster shots greatly reduce serious illness, hospitalizations and deaths.

Anne Thomas, a 64-year-old IT analyst in Westerly, Rhode Island, said she's fully vaccinated and boosted and also tries to stay safe by mostly staying home while her state has one of the highest COVID-19 case rates in the U.S.

"I have no doubt at all that these viruses are going to continue to mutate and we're going to be dealing with this for a very long time," she said.

Ray likened vaccines to armor for humanity that greatly hinders viral spread even if it doesn't completely stop it. For a virus that spreads exponentially, he said, "anything that curbs transmission can have a great effect." Also, when vaccinated people get sick, Ray said their illness is usually milder and clears more quickly, leaving less time to spawn dangerous variants.

Experts say the virus won't become endemic like the flu as long as global vaccination rates are so low. During a recent press conference, WHO Director-General Tedros Adhanom Ghebreyesus said that protecting people from future variants -- including those that may be fully resistant to today's shots -- depends on ending global vaccine inequity.

Tedros said he'd like to see 70% of people in every country vaccinated by mid-year. Currently, there are dozens of countries where less than a quarter of the population is fully vaccinated, according to Johns Hopkins University statistics. And in the United States, many people continue to resist available vaccines.

"These huge unvaccinated swaths in the U.S., Africa, Asia, Latin America and elsewhere are basically variant factories," said Dr. Prabhat Jha of the Centre for Global Health Research at St. Michael's Hospital in Toronto. "It's been a colossal failure in global leadership that we have not been able to do this."

In the meantime, new variants are inevitable, said Louis Mansky, director of the Institute for Molecular Virology at the University of Minnesota.

With so many unvaccinated people, he said, "the virus is still kind of in control of what's going on."

https://www.ctvnews.ca/health/coronavirus/expect-more-worrisome-variants-after-omicron-scientists-say-1.5741464

RSV More Prevalent Than COVID-19 In Colorado Children: Chief Medical Officer

 by Meiling Lee via The Epoch Times (emphasis ours),

The respiratory syncytial virus (RSV) is affecting children in Colorado more than COVID-19, according to a chief medical officer of Rocky Mountain Hospital for Children.

RSV is very contagious and very prevalent in the school system as well as throughout daycare centers and in homes,” Dr. Reginald Washington told FOX31 KDVR-TV on Jan. 12, adding that “COVID is increasing in its prevalence” and impacting children the second most, with the adenovirus being third.

RSV is a common respiratory virus that causes cold-like symptoms in people of all ages. Doctors say that the virus is so common that many children will have been infected with it before they are two years old.

RSV is mild in most children and goes away in a week or two but for some—who are immunocompromised or have a lung or heart disease—it can be quite severe.

RSV outbreaks usually occur from the fall through the spring, but an increase in RSV cases across the Southern parts of the United States prompted the Centers for Disease Control and Prevention (CDC) to issue a health advisory in June 2021.

Other countries also experienced a spike in RSV out of season. Public Health England, responsible for improving and protecting the country’s health and wellbeing, issued a notice encouraging parents “to look out for symptoms of severe infection in at-risk children” in July 2021. The agency says the increase was a result of the “various restrictions in place [during the winter of 2020] to reduce the spread of coronavirus (COVID-19), there were far fewer infections in younger people” that “many will not have developed immunity.”

Doctors in Queensland, Australia saw a significant rise in RSV cases in children between January and April of last year. Summer in Australia began Dec. 1, 2020, and ended on Feb. 28, 2021. The northeastern state recorded a total of 378 RSV cases in 2021 compared to 88 cases for all of 2019 and 70 cases in 2020.

Dr. Damian Roland, honorary professor of pediatric emergency medicine at Leicester University said that regardless of the disease, the focus should be on the signs and symptoms of the child, and not making parents afraid of the illness.

“From [the] parent point of view [it] doesn’t matter if [the] child has RSV, #COVID19 or [an]other virus. Decision making should be on their wellness not the disease,” Roland said on Twitter on Jan. 12.

He added, “My comment is we are creating fear in parents of particular diseases rather than how their child is. If your child has fever but is well & drinking the cause of that fever is irrelevant (but please get a COVID test as per national policy).”

Dr. Lynora Saxinger, infectious diseases expert and associate professor at the University of Alberta listed the symptoms that parents should be aware of and when to bring their child to the doctor or call Emergency Medical Services.

“Listen. Red flag symptoms for KIDS with virus infection: (Both RSV which is generally tough at this time of year, and has come back after a year off, and COVID19): my colleagues are seeing BOTH viruses causing ‘croup’—even in older kids,” Saxinger wrote on Twitter on Jan. 12.

RSV causes “an estimated 33.1 million acute lower respiratory tract infections worldwide and 3.2 million hospitalizations in children under 5 years,” according to The Lancet Respiratory Medicine.

The CDC says that there is currently no specific treatment for infection with RSV, but the World Health Organization (WHO) says that a vaccine may be “available in the near future.”

Fortunately, several vaccine candidates are now in the human testing phase targeting young children, older adults, and pregnant women, and an effective safe vaccine is likely to be available in the near future,” the WHO said.

https://www.zerohedge.com/medical/rsv-more-prevalent-covid-19-colorado-children-chief-medical-officer